Heart failure with reduced ejection fraction, Renal impairment
Conditions
Brief summary
The volumetric fraction (%) of the renal cortex with increased perfusion from baseline to Day 8, compared to placebo, as measured by quantitative parametric mapping using PET.
Detailed description
Safety and tolerability will be evaluated in terms of AEs, vital signs, clinical laboratory assessments, and ECG.
Interventions
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The volumetric fraction (%) of the renal cortex with increased perfusion from baseline to Day 8, compared to placebo, as measured by quantitative parametric mapping using PET. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability will be evaluated in terms of AEs, vital signs, clinical laboratory assessments, and ECG. | — |
Countries
Sweden
Outcome results
None listed